Background
==========

We recently discovered two novel transcripts (CT-RCC-8 and CT-RCC-9) from HERV-E provirus located on chromosome 6q expressed at variable levels in \>50% of renal cell carcinoma (RCC) samples but not in normal tissues or other tumors. We also identified a peptide antigen encoded by both of these HERV-E transcripts that was recognized by RCC-reactive T-cells isolated from a patient with metastatic RCC who had dramatic regression of tumor following a non-myeloablative allogeneic stem cell transplant \[[@B1]\].

Results
=======

Here, we show that HERV-E expression occurs only in clear cell variants of RCC (ccRCC) that demonstrate loss of normal Von Hippel-Lindau (VHL) protein. VHL transgenes introduced into VHL deficient ccRCC cell lines suppressed HERV-E expression implying that VHL controls provirus activity. Loss of functional pVHL has previously been shown to increase expression of the hypoxia-inducible factors HIF-1α and HIF-2α. We found a strong correlation between the transcriptional activity of HIF-2α and HERV-E provirus activation. We also found that expression of the HERV-E in ccRCC cell lines correlated with the demethylation of the 5\'LTR while normal tissues and ccRCC cell lines without HERV-E expression showed strong CpG methylation in this region. Once activated, HIF-2α binds DNA at the consensus HRE (core HRE sequence is CGTG) in the target gene promoters, and a HRE motif was identified in 5\'LTR of the HERV-E. It is therefore possible that methylation of 5\'LTR CpGs including the HRE CpG can explain silencing of HERV-E even in the presence of active transcriptional factors. The mechanism protecting the HERV-E promoter from methylation in VHL defective ccRCC lines leading to expression of proviral genes remains under investigation.

Conclusion
==========

These findings provide insight into mechanisms regulating HERV activation in human malignancies. The contribution of HERV-E to kidney tumorigenesis warrants further elucidation.
